IP Library Granted Patent US 7,727,730
Granted Patent B2
US 7,727,730 · App. 11/609,123 · Granted Jun 1, 2010

Methods and kits for detection of thromboxane A2 metabolites

Assignee: Corgenix Medical Corporation
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,727,730
App. No.
11/609,123
Granted
Jun 1, 2010
Kind
B2
Abstract

Methods, compositions and kits are provided for measuring aspirin's anti-thrombotic effectiveness on a subject. Included are a novel assay for quickly and specifically measuring TxA2 metabolite levels in urine and correlating the levels with aspirin dose in a subject. The methods, compositions and kits utilize a novel anti TxA2 metabolite antibody.

Claims (12)

1. A kit for measuring aspirin responsiveness by detecting 11-dehydro thromboxane B 2 and 11-dehydro-2,3-dinor thromboxane B 2 in a urine sample from a subject treated with aspirin, the kit comprising:

a monoclonal antibody selectively produced to bind 11-dehydro thromboxane B 2 and 11-dehydro-2,3-dinor thromboxane B 2 ; and

a signal molecule capable of competing with 11-dehydro thromboxane B 2 and 11-dehydro-2,3-dinor thromboxane B 2 in the urine sample for binding to the monoclonal antibody;

wherein the 11-dehydro thromboxane B 2 and 11-dehydro-2,3-dinor thromboxane B 2 in the subject's urine sample competes with a known amount of signal molecule for binding to the monoclonal antibody thereby indicating the amount of the 11-dehydro thromboxane B 2 and 11-dehydro-2,3-dinor thromboxane B 2 in the urine, and

wherein response to aspirin shows a decreased amount of 11-dehydro thromboxane B 2 and 11-dehydro-2,3-dinor thromboxane B 2 in the subject's urine relative to a standard and/or the amount in the urine from same subject or a different subject not treated with aspirin.

2. The kit of claim 1 further comprising:

a substrate modified for capture of the monoclonal antibody and for provision of a constrained space to contact the monoclonal antibody with both the signal molecule and urine sample.

3. The kit of claim 1 wherein the monoclonal antibody recognizes an epitope common to both 11-dehydro thromboxane B 2 and 11-dehydro-2,3-dinor thromboxane B 2 .

4. The kit of claim 3 wherein the monoclonal antibody recognizes the 11-dehydro Thromboxane B 2 metabolite and 11-dehydro-2,3-dinor Thromboxane B 2 metabolite with similar binding ratios, the ratio of 11-dehydro Thromboxane B 2 : 11-dehydro-2,3-dinor Thromboxane B 2 is from 0.5:1 to 1:0.5.

5. The kit of claim 4 wherein the ratio of 11-dehydro Thromboxane B2: 11-dehydro-2,3-dinor Thromboxane B 2 is from 0.6:1 to 1:06.

6. The kit of claim 2 wherein the substrate is modified with a goat anti-mouse antibody capable of tethering the monoclonal antibody to the substrate.

7. The kit of claim 1 wherein the monoclonal antibody exhibits little or no reactivity toward 2,3 dinor TxB2 or TxB2.

Assignments (7)
RELEASE OF SECURITY INTEREST Recorded Sep 3, 2021
From: ARES MANAGEMENT LIMITED, AS SECURITY AGENT
To: CORGENIX MEDICAL CORPORATION
Reel/Frame 057387/0507 →
IP SECURITY AGREEMENT SUPPLEMENT Recorded May 1, 2015
From: CORGENIX MEDICAL CORPORATION
To: ARES MANAGEMENT LIMITED, AS SECURITY AGENT
Reel/Frame 035561/0593 →
RELEASE OF SECURITY INTEREST Recorded Jul 11, 2011
From: BROADOAK CAPITAL PARTNERS, LLC
To: CAYMAN CHEMICAL COMPANY
Reel/Frame 026574/0808 →
SECURITY AGREEMENT Recorded Jul 20, 2010
From: CAYMAN CHEMICAL COMPANY, INCORPORATED
To: BROADOAK CAPITAL PARTNERS, LLC, AS AGENT
Reel/Frame 024710/0623 →
CORRECTIVE ASSIGNMENT TO CORRECT THE CORR. ASSIGN TO CORRECT US APPL. NO. AS 11/609,123 FROM INVENTORS F. JON GESKE AND AMY WHITTIER TO CORGENIX MEDICAL CORPORATION PREVIOUSLY RECORDED ON REEL 019275 FRAME 0232. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Jun 15, 2010
From: GESKE, F. JON; WHITTIER, AMY
To: CORGENIX MEDICAL CORPORATION
Reel/Frame 024534/0483 →
CORRECTIVE ASSIGNMENT TO CORRECT THE APPLICATION NUMBER NEEDS TO BE CHANGED FROM 11/609,126 TO 11/609,123 PREVIOUSLY RECORDED ON REEL 019255 FRAME 0668. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT OF ENTIRE INTEREST. Recorded May 10, 2007
From: TEW, DANIEL; MAXEY, KIRK M.; GESKE, F. JON; WHITTIER, ANY
To: CAYMAN CHEMICAL COMPANY; CORGENIX MEDICAL CORPORATION
Reel/Frame 019275/0232 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 7, 2007
From: TEW, DANIEL; MAXEY, KIRK M.; GESKE, F. JON; WHITTIER, AMY
To: CAYMAN CHEMICAL COMPANY; CORGENIX MEDICAL CORPORATION
Reel/Frame 019255/0668 →
Continuity (3)
Provisional Application 6074878800 · Dec 9, 2005
Provisional Application 6079342800 · Apr 19, 2006
Related Publication 20070202556A1 · Aug 30, 2007